Henlius and Sermonix Partner to Develop Lasofoxifene for Breast Cancer
Shots:
- As per the agreement, Sermonix obtains the worldwide rights while Henlius gains exclusive rights and sublicenses to lasofoxifene in China for two indications of ER+/HER2- breast cancer
- Sermonix has received the upfront payment and will further receive an additional milestone payment of $58M along with the royalties upon commercialization by Henlius
- Furthermore, the P-III (ELAINE-3) trial of lasofoxifene and Verzenio (abemaciclib) vs fulvestrant and Verzenio in pre- and post-menopausal patients (n=400) with ESR1mutated locally advanced/metastatic ER+/HER2- breast cancer will be funded by Henlius. It will also handle the regulatory approval, post-marketing manufacturing and commercialization in China
Ref: Globenewswire | Image: Henlius
Related News:- Henlius Announces the Acceptance of NDA Application by NMPA for Hansizhuang to Treat Esophageal cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
